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168CD34 afﬁnity pheresis attenuates a surge among
circulating progenitor cells following vascular injury
Adriana Harbuzariu, MD,a,b Justine Kim, BS,c E. Michael Meyer, BA,d Albert D. Donnenberg, PhD,b,d,e
and Bryan W. Tillman, MD, PhD,a,b Pittsburgh, Pa
Background: Intimal hyperplasia (restenosis) is an exaggerated healing response leading to failure of half of vascular
interventions. Increasing evidence suggests that circulating progenitor cells contribute to intimal pathology, and clinical
studies have demonstrated a correlation between progenitor cells and the incidence of restenosis after cardiovascular
interventions. The aims of this study were to characterize the temporal response of CD34D progenitors following
vascular injury in an ovine model and to evaluate an afﬁnity pheresis approach to attenuate this response.
Methods: An ovine model underwent either operative vascular injury or a nonvascular surgery (n [ 3 per group). Blood
was examined perioperatively over 2 weeks by ﬂow cytometry. Next, an afﬁnity pheresis approach to mediate systemic
depletion of CD34 progenitors was designed. Custom agarose pheresis matrix with antibody afﬁnity toward CD34 or an
isotype control was evaluated in vitro. Next, following vascular injury, sheep underwent perioperative whole blood
volume pheresis toward either the progenitor cell marker CD34 (n [ 3) or an isotype control (n [ 4) for 14 days.
Animals were monitored by physical exam as well as complete blood counts. Cells recovered by pheresis were eluted and
examined by ﬂow cytometry.
Results: Flow cytometry revealed a focal surge of circulating CD34 cells after vascular injury but not among surgical
controls (P [ .05). Toward the goal of an approach to attenuate the surge of CD34 progenitors, an evaluation of
high-ﬂow afﬁnity matrix revealed efﬁcacy in removal of progenitors from ovine blood in vitro. Next, a separate group of
animals undergoing afﬁnity pheresis after vascular injury was evaluated to mediate systemic depletion of CD34D cells.
Again, a surge of CD34D cells was observed among isotype pheresis animals following vascular intervention but was
attenuated over 20-fold by a CD34 pheresis approach (P[ .029). Furthermore, an average of 77 million CD34-positive
cells were eluted from the CD34 pheresis matrix. Despite multiple sessions of pheresis, complete blood counts remained
essentially unchanged over 2 weeks.
Conclusions: Despite evidence suggesting a role for CD34D circulating progenitor cells in restenotic pathology, the
temporal pattern of CD34 progenitors after vascular injury has not been previously deﬁned. We have demonstrated
a surge among circulating CD34D cells that appears conﬁned to procedures involving vascular injury and that this event
seems to occur early after vascular injury. We further conclude that CD34 afﬁnity pheresis attenuates the surge. This
approach for direct depletion of progenitors may have important implications for the study of progenitors in vascular
restenosis. (J Vasc Surg 2014;59:1686-94.)
Clinical Relevance: Restenosis is a major cause of failure after vascular inteventions. Progenitor cells in the blood are
believed to contribute to this disease, and published human studies reveal an association between these cells and increased
incidence of restenosis. Our ovine study characterized the pattern of CD34D progenitor cells after vascular injury and
suggests an early, focal surge event. We further demonstrate a novel pheresis approach to reduce these cells in the
bloodstream. This study offers new insights on the progenitor cell changes that follow vascular injury and may provide
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6Restenosis and late graft failure threaten the durability
of endovascular and open vascular procedures alike. Up to
half of endovascular and open lower extremity bypasses will
occlude in 5 years,1,2 half of vascular access grafts in
18 months,3 and 30% angiographic stenosis among bare
metal coronary stents by 1 year.4 Even after aggressive
surveillance and reintervention on these recurrent lesions,
longevity remains poor. A common theme of failure among
these seemingly diverse vascular beds is the pathology
known as intimal hyperplasia. Intimal hyperplasia is charac-
terized by proliferation of smooth muscle cells and extra-
cellular matrix that ultimately limits luminal diameter and
leads to vessel occlusion. This pathology has increased
the need for both surveillance as well as additional interven-
tions, contributing costs to the health care system and
increasing rates of limb loss and death. While drug-
eluting stents have proven effective in reducing some
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technology in peripheral vascular beds include the longer
length of lesions, greater complexity in the composition
of the plaques, restrictions on use at points of anatomic
ﬂexion or bifurcation, and small but signiﬁcant risk of acute
thrombosis.5,6 For these reasons, further understanding of
the pathology of intimal hyperplasia is essential toward
improving patient outcomes after vascular interventions.
Multiple authors have suggested a role of bone
marrow-derived progenitors in the pathology of intimal
hyperplasia.7-14 Even some authors who have challenged
a direct cellular contribution to intimal lesions have noted
increases among signaling molecules known to be involved
in bone marrow mobilization of progenitors.15 This would
suggest some contribution of circulating progenitors, even
if not at a cellular level. Most importantly, multiple groups
have highlighted an increased incidence of coronary
restenosis among patients with increased numbers of
circulating progenitors.16,17 Several laboratories have
described a vascular injury signal that mediates both circu-
lating progenitor mobilization but also homing to sites of
injury.18-20 It remains unclear, however, if mobilization
of these cells is limited to surgeries involving macrovascular
injury, or merely a generalized injury response to surgical
stress.
In summary, there remains controversy regarding the
role of circulating progenitors in restenosis. The primary
aim of this study was to document the temporal pattern
of circulating progenitor cells after vascular injury and to
compare these results with the response after a non-
vascular surgery in a large animal model. As in the human
condition, the marker CD34 has been previously deﬁned as
a marker of hematopoietic progenitor cells with colony-
forming activity in sheep.21 A second objective of this study
was to evaluate a short-term afﬁnity pheresis approach to
mediate depletion of circulating progenitors and the impact
if any on mature hematopoietic cells. Despite the apparent
technical simplicity of progenitor depletion, selective
afﬁnity depletion of progenitor cells from the circulation
has not been described previously in the literature.
METHODS
Afﬁnity antibodies. 8D11 antibody reactive to ovine
CD34 was characterized21 and kindly provided by Dr
Christopher Porada (University of Nevada, Reno, Nev).
This antibody was manufactured by Aldevron (Freiburg,
Germany). An isotype-matched IgG1 control antibody was
purchased from MP Biomedical (Solon, Ohio).
Preparation of afﬁnity matrix. For the creation of
macro agarose afﬁnity beads, plain agarose beads with
a diameter range of 150 mm to 300 mm (ABT, Madrid,
Spain) were functionalized with N,N disuccinimidyl
carbonate (DSC; Sigma-Aldrich, St Louis, Mo) using
some minor modiﬁcations for the protocol of Barkawi.22
Brieﬂy, agarose beads were rinsed with graded aqueous
and acetonewashes until a ﬁnal rinse with dry acetone (Acros
Organics, Geel, Belgium). DSC was dissolved to a concen-
tration of 0.26 M in acetone (dry) and added to theanhydrous beads. Dimethylaminopyridine (Sigma-Aldrich)
was dissolved in dry acetone to a concentration of 0.65 M
and then added dropwise to the DSC/antibody mixture.
After 6 hours of incubation at room temperature, beadswere
rinsed with serial rinses of dry acetone (dry), propanol
(dry), and ﬁnally, phosphate-buffered saline (PBS).
Immediately following the saline rinse, 8D11 antibody
or MOPC were added at a ratio of 1 mg per 15 mL of set-
tled beads. Alternately, CD34 antibody was conjugated
as previously described using commercially available N-
hydroxysuccinimide (NHS) Fastﬂow Sepharose beads (GE
Healthcare, Buckinghamshire, United Kingdom).23 As
previously described, only beads ﬁltered for size >70 mm
were used for conjugation.
In vitro cell depletion assay. Specimens of 35 mL of
heparinized ovine peripheral blood were incubated with
conditions of no beads, NHS afﬁnity beads, custom macro
CD34 afﬁnity beads, and isotype control macro afﬁnity
beads for 30 minutes at 37. DSC and NHS beads were
prepared with equivalent antibody mass of antibody. Beads
were then removed with 70-mm mesh ﬁlters (Fisher, Pitts-
burgh, Pa). Leukocytes were recovered by gradient centrifu-
gation (Histopaque 1077; Sigma-Aldrich) and evaluated by
ﬂow cytometry.
Animals. Female Dorset cross sheep between the ages
of 4 and 6 months were purchased from an approved
University of Pittsburgh vendor. All procedures were
approved by the University of Pittsburgh Institutional
Animal Care and Use Committee. Sheep were monitored
perioperatively for evidence of neurologic, cardiovascular,
allergic, or pulmonary complications. Animals were fed
Rumilab chow (PMI, St. Louis, Mo).
Vascular injury model. Sheep were allocated into two
groups, including control surgery with exposure but not
injury of the vessels (n ¼ 3) and a vascular injury group
that underwent placement of an arteriovenous graft and
a contralateral carotid angioplasty (n ¼ 3). For the control
group, the carotid vessels were exposed but not injured on
both sides. Heparin (APP Pharmaceuticals, Schaumburg,
Ill) was administered at 100 units per kg to all animals.
In the vascular injury group, a 6-mm polytetraﬂuoro-
ethylene graft was placed between the carotid artery and
jugular vein in an arteriovenous loop graft conﬁguration
using 6-0 polypropylene suture (Covidien, Mansﬁeld,
Mass). The left carotid was then exposed and underwent
balloon angioplasty injury with a 6-mm balloon (Ultra-thin
SDS; Boston Scientiﬁc, Natick, Mass) that was inﬂated
three times for the injury. Incisions were closed with
absorbable suture in two layers.
Afﬁnity pheresis. Pheresis groups included sheep that
all underwent vascular injury and were divided into groups
of isotype (n ¼ 4) and CD34 afﬁnity pheresis (n ¼ 3).
Under general anesthesia, a dual-lumen high-ﬂow dialysis
catheter (Covidien) was placed percutaneously in the
internal jugular vein, and ﬂow was initiated through the
saline-primed pheresis circuit prior to incision. A centrif-
ugal perfusion pump (Biomedicus; Medtronic, Minneap-
olis, Minn) was used to perfuse blood from the dialysis
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animal. Afﬁnity pheresis was initiated prior to the vascular
injury (postoperative day 0), and a 90-minute pheresis was
complete by the time of restoration of blood ﬂow. Blood
specimens were drawn before and after the initial and after
each subsequent pheresis sessions. Following 2 more days
of induction pheresis (days 1 and 2), 30-minute pheresis
occurred at a maintenance schedule on days 4, 7, 9, 11,
and 14. The 30-minute duration of pheresis was based on
calculation of the time to cycle the entire blood volume
over the pheresis column twice, with an extended period of
90 minutes for the ﬁrst pheresis. Following each pheresis
session, the pheresis circuit was rinsed with warm normal
saline to return all unbound blood and cells to the animal.
Afﬁnity column cell elution. Cells were eluted from
the afﬁnity columns following the ﬁrst three pheresis
sessions of each animal. Saline-rinsed beads were trypsi-
nized (0.05% Trypsin e EDTA; Invitrogen, Grand Island,
NY) for 10 minutes at 37. Trypsin was neutralized, and
the cells were centrifuged and plated in a glass dish over-
night in RPMI with 10% fetal calf serum (Hyclone;
Thermo-Fisher Scientiﬁc, Pittsburgh, Pa). Eluted cells
were counted and examined by ﬂow cytometry.
Flow cytometry. Flow cytometry was conducted on an
initial prepheresis specimen and postpheresis specimens.
Cells eluted from the afﬁnity columns were also examined by
ﬂow cytometry. Peripheral blood mononuclear cells were
isolated from 5 mL sheep blood by Ficoll density gradient
(Histopaque 1077; Sigma-Aldrich). Single cells were sus-
pended in aliquots of 3  106 cells in 100 mL PBS. After
blocking the cells for 15 minutes with 10% mouse serum,
they were incubated for 45minutes with mouse monoclonal
antibodies conjugated with ﬂuorochromes, directed to
several progenitor cell markers: antisheep CD34-PECy7
CD34 antibody manually conjugated in the lab to PECy7
using Lynx Rapid RPE-Cy7 Antibody Conjugation Kit
(AbD Serotec, Raleigh, NC) and antisheep CD45-FITC
(AbD Serotec); along with antihuman VEGFR2( ﬂk-1)-
PerCpCy5.5 purchased from Biolegend (San Diego,
Calif), antihuman CD133/1(AC133)-APC from Miltenyi
Biotec (Auburn, Calif). Appropriate matched isotype
controls were used. Samples were then washed in PBS and
ﬁxed in 2% paraformaldehyde for 20 minutes at room
temperature. After another wash using 0.5%BSA in PBS, the
cells were permeabilized for 10 minutes using a 0.1% sap-
onin þ 0.5% BSA solution in PBS. Finally, the cells were
washed and resuspended in PBS, and after adding DAPI
(Invitrogen), they were analyzed using a CyAN ADP high-
speed analyzer (Beckman Coulter, Inc, Fullerton, Calif).
The data ﬁles were analyzed using Summit 4.3 Version
Software (Beckman Coulter, Inc). For analysis of cytometric
data, an approach of sequential gating was used to exclude
doublets (cell clusters), CD34 negative cells, and ﬁnally red
cells and debris. The backscatter of the resulting events
reveal the population of high positive CD34 cells. In addi-
tion, isotype control thresholds were set at ﬂuorescence
intensity <1%. Cells eluted from the afﬁnity column were
directly stained in a similar fashion.Complete blood counts. Complete blood counts
were drawn preoperatively and then weekly to assess for
changes among traditional clinical parameters including
platelet count, white blood cell count, neutrophils, and
hemoglobin (Marshﬁeld Labs, Cleveland, Ohio).
Statistics. Results from in vitro were analyzed with
a Student t-test on postoperative day 1. Results among
animals undergoing nonvascular and vascular surgeries
and those treated with pheresis by isotype or CD34
pheresis were compared using a Mann-Whitney test at
postoperative day 1 on absolute cell counts of 300,000
events.
RESULTS
Balloon angioplasty mediates endothelial injury in
the ovine model. The ovine model has been previously
described for several contexts of vascular reconstruction
and graft stenosis.24-27 While angioplasty is recognized
clinically and among several animal models to cause endo-
thelial injury, it has not been explicitly demonstrated in the
ovine setting. In order to evaluate the efﬁcacy of a balloon-
based approach for endothelial injury, acute balloon-injured
carotid was compared with 4-month chronic injured and
noninjured carotid arteries as demonstration of this model.
Scanning electronmicroscope examination (n¼ 3) conﬁrms
a denuded endothelial monolayer in the acute injured
specimens with re-endothelialization noted in chronic and
noninjured specimens (Fig 1).
A surge of peripheral CD34-positive cells accom-
panies vascular injury but not nonvascular surgeries.
Vascular injury is known to initiate a cascade of signals that
are associated with mobilization of bone marrow progeni-
tors.20 Given the potential roles of bone marrow-derived
progenitors, it is not known if mobilization of progenitors
is speciﬁc to vascular injury or to surgical stress in general.
For this reason, the mobilization of CD34-positive cells
into the blood was compared between animals following
vascular injury and control surgical procedures. Blood
specimens were drawn before surgery and then on post-
operative days 0, 1, 2, 4, 7, 9, 11, 14, and 16, followed by
assessment by ﬂow cytometry (Fig 2). Following vascular
injury (n ¼ 3), a ﬁvefold surge of CD34 cells was observed
on postoperative day 1 (P ¼ .05) that was not observed
among animals undergoing control vessel exposure surgery
(n ¼ 3; Fig 3). In order to exclude mature cells, we
examined the marker CD45 and observed similar trends
among CD34þCD45- cells. While variability among
CD34 cell magnitude was observed, a surge was noted
among all animals. This variation may be a reﬂection of the
heterogeneous animals of this study.
Custom beads with afﬁnity toward CD34 mediate
depletion from whole blood. While methods exist to
increase certain types of cells in the blood, such as
G-CSF or erythropoietin, there are currently no approaches
to mediate depletion of speciﬁc populations of circulating
cells short of bone marrow ablation. Our group has
previously described the use of an afﬁnity pheresis with
commercially available NHS sepharose beads for the
Fig 2. Flow analysis of sheep for CD34-positive cells. Blood specimens drawn preoperatively, or from the ﬁrst post-
operative day after nonvascular or vascular surgery were compared. A total of 300,000 events from peripheral blood
specimens were gated sequentially for singlet events, CD34 positivity, DAPI positivity, and ﬁnally backscattered to
reveal ﬁnal population of cells highly expressing CD34. Increased numbers of CD34-positive cells can be seen after
vascular injury (bottom right).
Fig 1. Carotid angioplasty mediates endothelial injury in an ovine model. Compared with uninjured native carotid
artery (A), acute balloon injury achieves endothelial injury (B) as shown in these scanning electron microscope images
of the luminal surface of the vessel (1200). By 4 months, the area of endothelial injury has re-endothelialized (C) in
these representative images (n ¼ 3).
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 6 Harbuzariu et al 1689purposes of cell recovery using only physiologic blood pres-
sure for propulsion of the pheresis.28 In order to adapt this
approach toward the demands of a circulatory depletion
and pump-based propulsion, we recognized limitations on
ﬂow rates through the small (70-165 mm) tightly packed
beads of our previous commercially available bead format.
To facilitate improved ﬂow rates and expected higher
volumes of blood using a cardiopulmonary perfusion
pump, a higher ﬂow system based on a larger bead format(150-300 mm) was developed. To compare the efﬁcacy of
our custom-conjugated beads with our previous standard,
we compared NHS beads conjugated to anti-CD34
antibody with macro beads that were unconjugated
(plain), conjugated to an isotype antibody (MOPC), or
conjugated to the anti-CD34 antibody by their capacity to
deplete CD34 cells from isolated blood samples in vitro.
As shown in Fig 4, our results suggest that CD34 afﬁnity
DSC beads deplete CD34-positive cells in a statistically
Fig 3. Surge of total CD34 and CD34-positive, lineage negative cells is observed among animals undergoing vascular
injury. Flow cytometry of sheep undergoing either control surgery without vascular injury (A andC) (n¼ 3) as compared
with sheep undergoing vascular injury (B andD) (n ¼ 3). Shown are percent CD34þ or CD34þ/CD45- cells from all
events. A and B reveal percent of CD34 cells and suggest a surge as high as sevenfold compared with baseline following
vascular injury (P ¼ .05 on postoperative day 1). C andD indicate the percent of CD34þ/CD45- cells, again revealing
a surge among lineage negative progenitors. Results are expressed as mean 6 standard error.
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control afﬁnity beads (P ¼ .01), and even relative to
commercially available NHS beads with afﬁnity for CD34
(P ¼ .02).
A CD34 afﬁnity column attenuates the surge of
CD34-positive cells after vascular injury. Based on the
successful depletion of CD34-positive cells in vitro, we
reasoned that an afﬁnity approach could attenuate the surge
among CD34 cells in the entire circulation of a large animal
model. This approach would provide a model to examine
the effects of progenitors in various contexts, including
intimal hyperplasia. To test this hypothesis, a new group of
animals was examined for the ability to achieve systemic
depletion of CD34 cells as measured by ﬂow cytometry.
Immediately prior to vascular injury on the day of surgery,
animals underwent pheresis using matrix with afﬁnity to
either CD34 or an isotype control. Compared with animals
undergoing vascular injury with an isotype control, afﬁnity
column animals undergoing pheresis with a CD34 afﬁnity
column demonstrated a 20-fold attenuation of CD34
response after vascular injury that was statistically signiﬁcant
(P ¼ .029; Fig 5). This relative depletion among animals
treated with CD34 afﬁnity pheresis was also observed when
marker combinations of CD34þ/CD45-, CD34þ/
VEGFR2þ and CD34þ/CD133þ were compared with
isotype-depleted animals. In our study, pheresis was well
tolerated with no evidence of neurologic, pulmonary, or
other observed side effects.
Cells eluted from a CD34 afﬁnity column reveal
high numbers of CD34-positive cells. As further conﬁr-
mation that our results in the peripheral blood were a resultof CD34 depletion, cells were enzymatically eluted from
isotype and CD34 afﬁnity matrix after pheresis. Following
enzymatic release, cells were allowed to recover receptor
expression overnight. Compared with the isotype column,
which yielded few eluted cells, a CD34 afﬁnity matrix
yielded between 35 and 158 million of CD34-positive
cells, which appear to surge in the ﬁrst pheresis days,
consistent with the day of maximal surge among peripheral
blood specimen analysis of isotype control-treated animals
(Fig 6).
Cell counts following depletion of progenitor
cells. Medical devices, particularly those associated with
blood, have been associated with complications that
include thrombocytopenia, anemia, and neutropenia. In
order to examine changes among other mature circulating
blood cells, a complete blood cell count was assessed at the
time of surgery and then weekly for 2 weeks. Despite acute
depletion of circulating progenitor cells among CD34 phe-
resis animals, no evidence of signiﬁcant changes were noted
in hemoglobin or platelet counts (Table). Interestingly,
a small but statistically signiﬁcant increase in neutrophils
was noted among animals following CD34 pheresis,
although this remained well within the normal range for
the ovine model. Also, white blood cell values were slightly
increased among animals treated with isotype pheresis,
although again, this remained well within normal range.
DISCUSSION
Intimal hyperplasia has a profound adverse impact on
the outcomes of vascular interventions as well as patient
outcome. Clinically, restenosis encompasses a wide
Fig 4. CD34 afﬁnity agarose beads prepared with N,N0-
Disuccinimidyl carbonate (DSC) reveal speciﬁc depletion of CD34
cells from ovine blood specimens. Blood specimens were incubated
with no beads, commercial N-hydroxysuccinimide (NHS) sepharose
beads conjugated to CD34 antibody, plain agarose beads, isotype
control antibody (MOPC) DSC beads, or CD34 conjugated DSC
beads (n ¼ 3 for all conditions; standard error bars are shown).
CD34-afﬁnityDSCbeads depleteCD34-positive cells in a statistically
signiﬁcant manner relative to isotype control afﬁnity beads (P¼ .01).
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nary arteries, peripheral vasculature, and even those with
vascular access for dialysis. Poor long-term outcomes
underscore the need for new approaches toward prevention
of this important clinical dilemma. While drug-eluting
stents have proven effective in the coronary circulation,
they remain discouraged from use at ﬂexion points in the
peripheral vasculature due to fracture risk,5 limitations on
subsequent open bypass options, and possible increased
risk of thrombosis secondary to impaired local endothelial
repair.6 For these reasons, despite their utility in coronary
applications, alternative approaches to drug-eluting
stents are needed. Several studies have highlighted the
role of bone marrow-derived progenitors, as contributing
to between 20% and 66% of cells in intimal lesions.7,10-13
Although bone marrow-derived cells are widely known for
their roles in hematopoiesis and, more recently, their contri-
bution to endothelial repair,29 several authors have demon-
strated that CD34-positive cells can differentiate into cells
expressing smooth muscle markers.30,31 Among several
animal models, increased recruitment or mobilization of
progenitor cells was associated with accelerated intimal
disease following cardiovascular interventions.8,32 These
ﬁndings were echoed in the human condition by results of
the MAGIC trial, which was terminated prematurely due to
accelerated restenosis of patients treated with the progenitor
mobilization cytokine G-CSF following bare metal stent
placement.9
Whether progenitor cells directly contribute to the
cellular mass of intimal lesions remains an area ofcontroversy; however, even authors who have published
against direct cellular contribution have reported that
blockade of chemokines involved in progenitor cell mobili-
zation and homing, such as sdf1-alpha,15 can reduce intimal
pathology. Similar ﬁndings have been observed after
blockade of the c-kit positive cells.11 Of interest, drug-
eluting stents, the only currently available clinical therapy
to reduce intimal hyperplasia, involve the use of immuno-
suppressive agents. It is possible that progenitors mediate
an inﬂammatory microenvironment favorable for intimal
lesions. In summary, the literature appears to support that
bone marrow-derived progenitors play some role in intimal
pathology, whether by a direct cellular contribution or by
fostering a favorable inﬂammatory environment. Despite
the potential role in vascular restenosis, the temporal pattern
of circulatory progenitor cells after vascular injury has not, to
date, been deﬁned.
To provide insight on the pattern of circulating CD34-
positive progenitors after vascular injury, we have examined
a sheep model of vascular injury, consisting of an arteriove-
nous graft with contralateral carotid angioplasty. One
objective of this study was to determine whether a mobiliza-
tion of CD34 progenitor cells occurs after an open vascular
procedure and whether such a response is conﬁned to
vascular interventions or rather is just a generalized
response to surgical stress. Our ﬁndings suggest that there
is a surge of CD34-positive cells limited to animals under-
going vascular injury. Acknowledging the overlap of CD34
expression on other cells such as mast cells and endothelial
progenitor cells (EPC), we further analyzed our results and
found similar CD34 surge trends even when CD45þ (mast
cells) and CD133þ (EPC) events were excluded. Interest-
ingly, our control group inherently entailed microvascular
damage during surgery as well as needlestick cannulation
for blood draws. Despite these minor vascular injuries,
the control group still did not elicit a signiﬁcant CD34
mobilization in peripheral blood as compared with animals
with macrovascular injury. In some ways, the surge of
CD34 progenitors is not unexpected, given the role of
these cells in the repair of endothelial injury.29 With regards
to intimal pathology, however, previous human studies
have demonstrated that patients with increased numbers
of preprocedural17 and postprocedural16,33 CD34 positive
progenitors carry statistically higher risk for coronary reste-
nosis. The short longitudinal study of Inoue et al33 among
human coronary stent patients revealed both increases
among CD34 cells but also an increase of mobilization
cytokines such as G-CSF, suggesting these CD34þ cells
originate from the bone marrow reservoir. To date, there
have been no studies evaluating CD34 response after
open peripheral vascular procedures or comparing these
ﬁndings with nonvascular procedures. The results of this
study appear to address this important question, at least
in the ovine model.
A signiﬁcant hurdle toward evaluating whether circu-
lating progenitor cells are bystanders or play an active
role in intimal hyperplasia is the absence of approaches to
modulate progenitor cells in the circulation. While several
Fig 5. CD34 afﬁnity agarose beads attenuate the surge of CD34 cells following vascular injury. Shown are percent
CD34þ or CD34þ/CD45- cells from all events. Following vascular injury, a surge of CD34þ cells (A) and CD34þ/
CD45- (C) is seen despite pheresis with an isotype afﬁnity column (n ¼ 4). In contrast, a CD34 afﬁnity column (n ¼ 3)
attenuates the surge andmediates a relative state of depletion among both CD34þ (B) and CD34þ/CD45- cells (D). A
statistically signiﬁcant difference is observed among total CD34 expressing cells between the two groups (P ¼ .029 on
postoperative day 1). Results are expressed as mean 6 standard error.
Fig 6. CD34 afﬁnity column recovers large numbers of CD34-positive cells. Cells eluted following pheresis of animals
undergoing vascular injury were counted and examined by ﬂow cytometry. Relative to the rare cells recovered by an
isotype column (A), CD34 afﬁnity column (B) recovered an average of 77 million CD34-positive cells.
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they serve to increase and not decrease the numbers of cells
by either cytokine mobilization or direct cell infusion. In
contrast, the options for reducing cells in a speciﬁc manner
is more challenging. Leukapheresis removes cells relatively
nonspeciﬁcally based on cell density, often impacting other
nontarget cell types. Pharmacologic therapies to reduce
circulating progenitors are limited largely to chemothera-
peutic agents and are limited by bystander toxicity. For
these reasons, with currently available approaches, it
becomes difﬁcult to establish a depletion of speciﬁc cell
types for a limited period of time.
We hypothesized that an afﬁnity pheresis approach of
the entire blood volume directed toward CD34 may atten-
uate the surge response of target CD34 cells in a large
animal model. For this purpose, we applied a previouslydescribed afﬁnity pheresis approach.23 In examining our
results, it is noteworthy that the magnitude of the CD34
surge of vascular injury with isotype pheresis appears
substantially higher than observed among animals who
underwent vascular injury without pheresis, approaching
fourfold when comparing means on postoperative day 1.
Conceivably, this may represent a response to the compo-
nents of the pheresis circuit. Alternately, the high ﬂow and
intravenous turbulence of the pheresis treatment may
exacerbate the vascular injury and thereby the CD34
mobilization. While it merits further investigation, this
ﬁnding is certainly intriguing, considering the exceptionally
rapid stenosis pattern observed clinically with high-ﬂow
dialysis catheters and turbulent surgical arteriovenous
access. Despite this more accentuated mobilization of
CD34 cells in the peripheral circulation among isotype
Table. Complete blood counts are minimally changed following depletion of CD34 cells by afﬁnity pheresis
Prepheresis Post 1 week
P value
Post 2 weeks
P valueMean SD Mean SD Mean SD
Isotype Hemoglobin 8.8 0.8 9.0 .9 .9003 8.8 0.9 .8756
Plateletsa 384 131.7 574.0 22.2 .3793 492.3 118.9 .5825
White blood cells 4.4 1.1 5.4 .2 .0277 5.6 0.8 .0204
Segmented neutrophils 1.6 0.4 1.8 1.0 .6666 2.0 0.8 .5446
CD34 Hemoglobin 8.3 0.4 8.3 .9 .9445 9.0 1.1 .3908
Platelets 592.3 131.7 668.0 22.2 .6548 586.0 112.1 .9152
White blood cells 4.4 1.1 5.6 .2 .2570 6.5 1.5 .0746
Segmented neutrophils 1.6 0.8 3.1 1.4 .0841 3.7 0.8 .0289
SD, Standard deviation.
Complete blood counts were drawn before vascular injury and subsequently at 1 and 2 weeks. Shown are blood counts from animals undergoing MOPC
isotype pheresis (n ¼ 4) and CD34 afﬁnity pheresis (n ¼ 3). Small but statistically signiﬁcant increases were noted among white blood cells and segmented
neutrophils. Notably, these values remain well within the range of normal for the ovine model.
aPlatelets could not be assessed on two timepoints for one isotype pheresis animal. As a result, this animal was excluded from platelet comparison.
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not only attenuated the CD34 surge but also mediated
a relative state of depletion compared with baseline. Impor-
tantly, complete CD34 depletion was not achieved, which
may be related to either the large volume of distribution,
technical issues related to optimal binding under high
ﬂow conditions, or limits of detection of these rare cells.
Regardless, if CD34-positive cells do indeed play a role in
intimal lesions, it remains to be seen if complete depletion
is even necessary. It is conceivable that prevention of the
CD34 surge alone would be sufﬁcient to prevent resteno-
sis. One goal of our study that could not be achieved was
the assessment of the effect of CD34 depletion on intimal
change. Despite both published reports of rapid resteno-
sis,24 as well as our own published experience in the sheep
model,26 signiﬁcant restenosis was not observed among
controls at 4 months. As a result of regional availability,
the breed in this study differs from either of the two pub-
lished studies and may explain these ﬁndings.
Importantly, progenitors have been implicated in the
physiologic roles of both angiogenesis and wound heal-
ing.34,35 If progenitors are involved in restenosis, further
investigation will be essential to determine the speciﬁc
conditions and timing under which progenitors may play
a physiologic or pathologic role. Some medical devices
may result in changes in the complete blood count, such
as thrombocytopenia,36 neutropenia, and anemia.37 This
would seem especially probable for a pheresis approach
that removes the precursors to mature hematopoietic cells.
Despite our relative depleted state, there appeared to be
no deﬁciencies among white blood cells, platelets, or
hemoglobin after pheresis. A subtle but statistically signiﬁ-
cant neutrophilia was seen only among CD34 pheresis
animals but, importantly, remained well within the realm
of normal values for the ovine model. The results of this
study suggest a signiﬁcant progenitor mobilization event
at the time of vascular injury that may represent kindling
for the pathology of intimal hyperplasia. We expect that
the depletion approach described here may be a useful
tool to continue to explore the role of CD34-circulatingprogenitors in the development of intimal lesions. Direct
progenitor depletion may be especially important as
a tool to isolate the overlap of roles between vascular
smooth muscle cells and progenitor cells in this pathology.
Based on reports of clinical association between restenosis
in the setting of higher numbers of circulating progeni-
tors,16,17 this approach of direct progenitor depletion
may eventually have therapeutic utility, as well. To our
knowledge, no other previous study has allowed
intervention directly at the level of the progenitor cell.
This afﬁnity approach may also be useful in other disease
contexts where depletion of speciﬁc circulating cells is
desirable.
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